Evoke Pharma Statistics
Total Valuation
Evoke Pharma has a market cap or net worth of $3.79 million. The enterprise value is $4.05 million.
| Market Cap | 3.79M |
| Enterprise Value | 4.05M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 8.48 million shares outstanding. The number of shares has increased by 6.34% in one year.
| Shares Outstanding | 8.48M |
| Shares Change (YoY) | +6.34% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 9.65% |
| Owned by Institutions (%) | 37.96% |
| Float | 4.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| Forward PS | 0.26 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.25
| Current Ratio | 2.25 |
| Quick Ratio | 1.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.58 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -91.80% |
| Return on Capital (ROIC) | -307.00% |
| Revenue Per Employee | $1.30M |
| Profits Per Employee | -$1.95M |
| Employee Count | 4 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 0.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.69% in the last 52 weeks. The beta is 0.30, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.30 |
| 52-Week Price Change | -76.69% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 35.06 |
| Average Volume (30 Days) | 41,608 |
Short Selling Information
The latest short interest is 53,371, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 53,371 |
| Short Previous Month | 72,133 |
| Short % of Shares Out | 0.63% |
| Short % of Float | 1.22% |
| Short Ratio (days to cover) | 1.14 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $5.18 million and -$7.79 million in losses. Loss per share was -$2.33.
| Revenue | 5.18M |
| Gross Profit | 4.98M |
| Operating Income | -7.43M |
| Pretax Income | -7.79M |
| Net Income | -7.79M |
| EBITDA | -7.16M |
| EBIT | -7.29M |
| Loss Per Share | -$2.33 |
Balance Sheet
The company has $4.74 million in cash and $5.00 million in debt, giving a net cash position of -$260,574 or -$0.03 per share.
| Cash & Cash Equivalents | 4.74M |
| Total Debt | 5.00M |
| Net Cash | -260,574 |
| Net Cash Per Share | -$0.03 |
| Equity / Book Value | -2.58M |
| Book Value Per Share | -0.30 |
| Working Capital | 3.79M |
Cash Flow
| Operating Cash Flow | -4.98M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.98M |
| FCF Per Share | -$1.49 |
Margins
Gross margin is 96.10%, with operating and profit margins of -143.44% and -150.41%.
| Gross Margin | 96.10% |
| Operating Margin | -143.44% |
| Pretax Margin | -150.41% |
| Profit Margin | -150.41% |
| EBITDA Margin | -138.27% |
| EBIT Margin | -140.76% |
| FCF Margin | -96.22% |
Dividends & Yields
Evoke Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.34% |
| Shareholder Yield | -6.34% |
| Earnings Yield | -205.39% |
| FCF Yield | -131.40% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 23, 2022. It was a reverse split with a ratio of 1:12.
| Last Split Date | May 23, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
Evoke Pharma has an Altman Z-Score of -26.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -26.24 |
| Piotroski F-Score | 3 |